← board
MBIO
distress 5/10 · elevated risk$0.60+2%today-77% from 52w high
Lead: recurrent glioblastoma and high-grade astrocytomas
Revenue
pre-revenue
Liquidity
$16M
Runway
3.3 yrs
Shares 1y
+91%
Price & events
-43.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
-7.0%
1W
-13.4%
1M
-21.4%
3M
-42.9%
6M
-71.2%
1Y
-96.0%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $14.98M
- Volume
- 2.49K
- 52 Week Range
- $0.59 – $2.65
- Total Shares
- 24.98M
- Float Shares
- 5.35M
- Short %
- 1.52%
- % Held by Insiders
- 4.30%
- % Held by Institutions
- 9.47%
- RVOL
- 0.06x
- Beta
- 2.05
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- second half of 2025trial initiationsecondaryMB-109 · Initiate clinical trial of MB-109 (MB-101 + MB-108) for recurrent GBM and high-grade astrocytomas.SEC 8-K
- 2025-12-17withdrawalCD20 CAR-T · Terminated CD20 License Agreement with Fred HutchSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — recurrent glioblastoma and high-grade astrocytomas
- none identified
Recent news
- 2026-07-17Mustang Bio stock trades lower as cash runway and trial update shape outlook - Ad-hoc-news.de
- 2026-07-03MBIO Should I Buy - Intellectia AI
- 2026-06-25MBIO Q4 2024 Earnings: Massive EPS Miss as Pre-Revenue Biotech Faces Cash Burn Challenges - GAAP Earnings Report - Bölüm Sonu Canavarı
- 2026-06-23Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - ROE Trend Analysis - dars.gov.et
- 2026-06-10Mustang Bio Inc. (MBIO) Q4 2024 Earnings: EPS Misses by Wide Margin Amid No Revenue; Stock Declines - Downward Estimate Revision - dars.gov.et
- 2026-05-29Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage - Post-Earnings Reaction - dars.gov.et
- 2026-04-09Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet - Kavout | AI
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.